Ovid Therapeutics Inc. (FRA:1OT)

Market Cap	170.94M +225.1%
Revenue (ttm)	5.63M +945.9%
Net Income	-30.57M
EPS	-0.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	370
Open	1.470
Previous Close	1.420
Day's Range	1.470 - 1.470
52-Week Range	0.176 - 1.550
Beta	n/a
RSI	44.14
Earnings Date	Mar 11, 2026

About Ovid Therapeutics

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It develops OV350 IV, OV4071, and OV4041, an oral pr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 23
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1OT

Financial Performance

In 2024, Ovid Therapeutics's revenue was $566,000, an increase of 44.39% compared to the previous year's $392,000. Losses were -$25.98 million, -49.49% less than in 2023.

Financial numbers in USD